Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN AND BENZOYL PEROXIDE versus WYAMYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN AND BENZOYL PEROXIDE versus WYAMYCIN E.
ERYTHROMYCIN AND BENZOYL PEROXIDE vs WYAMYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. Benzoyl peroxide has bactericidal effects against Propionibacterium acnes, likely through the release of free radical oxygen that oxidizes bacterial proteins. It also has keratolytic and comedolytic properties.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Topical: Apply a thin layer to affected areas once daily in the evening.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
None Documented
None Documented
Erythromycin: 1.4–2.0 hours (terminal half-life in adults). Benzoyl peroxide: Not applicable; it is a topical agent with negligible systemic absorption.
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Erythromycin is primarily excreted via bile (fecal elimination) with approximately 15% excreted unchanged in urine. Benzoyl peroxide is degraded to benzoic acid, which is conjugated with glycine to form hippuric acid and excreted renally; less than 5% is excreted unchanged in urine.
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic